Interleukin-2-Based Biochemotherapy for Patients with Stage IV Melanoma: Long-Term Survivors Outside a Clinical Trial Setting

Publisher： Karger

E-ISSN： 1423-0232|73|1-2|33-40

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.1-2, 2008-03, pp. : 33-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Survival in Stage IV Melanoma after Repetitive Surgical Therapy

By  

Oncology Research and Treatment, Vol. 31, Iss. 5, 2008-04 ,pp. : 259-261

Karger

Access to resources Recommend Favorite

Efficacy and safety of bio‐chemotherapy with dacarbazine plus interleukin‐2 in patients with unresectable malignant melanoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 314-318

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2063-2071

Informa Healthcare

Access to resources Recommend Favorite

When to Perform Surgery in Stage IV Melanoma Patients?

By  

Oncology Research and Treatment, Vol. 31, Iss. 5, 2008-04 ,pp. : 226-227

Karger

Access to resources Recommend Favorite

Long‐term cause‐specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: A population‐based study of 28,844 patients

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2334-2342

John Wiley & Sons Inc

Access to resources Recommend Favorite